OSRH

8-K - OSR Health, Inc. (0001840425) (Filer)

The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders.To OSR Health Shareholders:I am aware that many of you are watching closely to see what comes next. I want to address some of your concerns directly and with specificity.OSR Health's stock is showing resilience this morning after a difficult session yesterday. In our opinion, that resilience reflects something real: the conviction of shareholders who understand this Company and its potential.WHAT

8-K - OSR Health, Inc. (0001840425) (Filer)

BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination") from the Nasdaq Listing Qualifications Department notifying the Company that its common stock and warrants are subject to delisting from The Nasdaq Capital Market as a result of the Company's failure to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2).Nasdaq Hearing RequestThe Company intends to request a hearing before the Nasdaq Independent Hearings Panel (the "Panel") to appeal the Staff Determination, pursuant to the procedures set forth

Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program. BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders.To Every OSR Health Shareholder, Wherever You Are:OSR Health is at an inflection point, one that I believe will be looked back upon as the moment this company's underlying value began to be recognized by the broader market. Before that recognition fully arrives, I want to speak directly to the shareholders who have been here all along, and to those who joined us over the past remarkable tw

10-Q - OSR Health, Inc. (0001840425) (Filer)

Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders.Dear Shareholders,Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close.As CEO of OSRH, I want to assure our shareholders that I remain deeply confident in the fundamental value we are buildin

8-K - OSR Health, Inc. (0001840425) (Filer)

8-K - OSR Health, Inc. (0001840425) (Filer)

BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Market ("Nasdaq") and the Company's Shareholder Loyalty CVR Program.The Company is clarifying that the statement in the prior release, "The communication affirms that our loyalty program is additive and gives shareholders clarity," should not be interpreted as indicating that Nasdaq has approved or endorsed the Shareholder Loyalty CVR Program.Nasdaq's earlier communication was a preliminary, verbal indication limited to the technical question of whether the program would result

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma.Prof. Wolfgang Wick, M.D., Chairman of the Neurology Clinic of Heidelberg University and the principal investigator of these trials, commented that "these results are indeed encouraging with regard to moving this concept further in the clinic".The

8-K - OSR Health, Inc. (0001840425) (Filer)

BELLEVUE, WA / ACCESS Newswire / July 31, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that the Nasdaq Stock Market ("Nasdaq") stated in a verbal communication with the Company that the Company's Shareholder Loyalty Contingent Value Rights (CVR) program will not result in any mechanical adjustment to the price of OSR Health's common stock - either upon the distribution of the CVRs or upon the delivery of additional shares of common stock to enrolled holders under the program.What this means for shareholders:No mechanical price adjustment. Nasdaq will not apply an ex-date or other downward adjustment to the OSRH share price in connection with the CVR d

DEF 14A - OSR Health, Inc. (0001840425) (Filer)

BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders.To Every OSR Health Shareholder:OSR Health is at an inflection point - one that I believe will be looked back upon as the moment this company's underlying value began to be recognized by the broader market. Before that recognition arrives, I want to speak to the shareholders who have been here all along.You chose to believe in what we are building at a time when it was not easy to hold. You have stayed through volatility, through noise, and through a share price that has not yet reflected what we believe this company is worth. I see

PRE 14A - OSR Health, Inc. (0001840425) (Filer)

The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date. It was previously mentioned that the pricing needed to be sustained over that time period. NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the p

NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the plan, which remains subject to legal counsel's opinion, with a record date targeted for July 31, 2026.Key Highlights From the Flash Report:Shareholder Loyalty Program via Contingent Value Rights:OSRH plans to distribute

Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones BELLEVUE, WA / ACCESS Newswire / June 25, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced a Shareholder Loyalty Program designed to reward the investors who hold OSRH stock over the long term. Under the program, the Company plans to distribute non-transferable Contingent Value Rights ("CVRs") to all shareholders of record tentatively as of July 31, 2026. One CVR for every share owned. The Board of Directors has authorized management to proceed with implementation, subject to receipt of a legal opinion confirming the applicable securities law requirements have bee

BELLEVUE, WA / ACCESS Newswire / June 22, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has officially changed its corporate name to OSR Health, Inc., a fresh identity that more directly reflects the Company's mission. The change became effective on June 11, 2026 upon the filing of a Certificate of Amendment with the Delaware Secretary of State.The rebrand is a clearer articulation of the Company's identity as a global health innovation platform operating across biotechnology, medical technology, life sciences, and wellness markets. While "OSR Holdings" described a corporate structure, OSR Health more directly reflects the Company's mission to improve health outcomes throug

8-K - OSR Health, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

DEFA14A - OSR Holdings, Inc. (0001840425) (Filer)

BELLEVUE, WA / ACCESS Newswire / June 3, 2026 / Dear Fellow Shareholders,As we move through 2026, I would like to provide an update on where OSR Holdings (NASDAQ:OSRH) stands today and how we are approaching the opportunities ahead:Strategic Focus and Business DevelopmentOver the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries.Vaximm recently executed a definitive licensing agreement for the VXM01 immunotherapy p

8-K - OSR Holdings, Inc. (0001840425) (Filer)